Five Things the Women’s Health Initiative Got Wrong — and What We Know Now

The Women’s Health Initiative changed hormone therapy practice overnight. When the combined estrogen-progestin arm was halted in July 2002, the headlines were unambiguous: hormone therapy causes breast cancer, heart attacks, and strokes. Millions of women discontinued their prescriptions. Millions more were never offered therapy. An entire generation of physicians was trained to approach hormone therapy with caution bordering on avoidance.

Twenty-four years later, the evidence has matured considerably. The WHI was an important study. It was also a deeply flawed one, and the conclusions drawn from it were applied far more broadly than the data supports.

1. The Hormones Tested Are Not the Hormones Used Today

The WHI combined arm used oral conjugated equine estrogens (Premarin) and medroxyprogesterone acetate (Provera). Neither is bioidentical.

Conjugated equine estrogens are derived from pregnant horse urine and contain multiple estrogen compounds, several of which are not found in the human body. Medroxyprogesterone acetate is a synthetic progestin with off-target activity on androgen and glucocorticoid receptors.

Modern bioidentical hormone therapy uses estradiol (molecularly identical to human estrogen) and micronized progesterone (molecularly identical to human progesterone). The metabolic behaviour, receptor binding, and safety profile of these molecules differ from the ones the WHI tested.

Applying the WHI’s findings to bioidentical hormone therapy is a category error. The molecules are different. The data is not transferable.

2. The Population Studied Was the Wrong Age

The average age of WHI participants at enrollment was 63. Many were 10 to 20 years past menopause. The study was designed to test whether hormone therapy could prevent chronic disease in older postmenopausal women, not whether it could support women through the menopausal transition.

This matters because the biological response to hormones changes with time since menopause. Vascular endothelium that has been estrogen-deprived for 15 years responds differently to estrogen than endothelium that has been deprived for 2 years. The “timing hypothesis,” supported by subsequent analyses including the WHI’s own age-stratified data, demonstrates that women who initiate hormone therapy within 10 years of menopause or before age 60 have significantly better cardiovascular outcomes than women who start later.

The WHI’s headline results were driven by the older cohort. Applying those results to a 51-year-old woman entering menopause is not supported by the study’s own subgroup analyses.

3. The Delivery Route Matters

The WHI used oral estrogen exclusively. Oral estrogens undergo first-pass hepatic metabolism, which increases the liver’s production of clotting factors (particularly factor VII and fibrinogen), CRP, and SHBG. These hepatic effects drive the thrombotic and inflammatory risks observed in the WHI.

Transdermal estrogen bypasses the liver entirely. Multiple observational studies and a large French case-control study have demonstrated that transdermal estrogen does not carry the same clotting risk as oral estrogen. A 2007 analysis in the British Medical Journal found that transdermal estrogen at standard doses was not associated with increased venous thromboembolism risk, while oral estrogen was.

The WHI’s cardiovascular and thrombotic findings are specific to the oral route. They do not apply to transdermal delivery.

4. The Progestin Was the Problem for Breast Cancer

The WHI had two arms. The combined estrogen-plus-progestin arm showed a modest increase in breast cancer incidence. The estrogen-only arm, in women who had undergone hysterectomy, showed a decrease in breast cancer incidence that persisted through 16 years of follow-up.

This finding isolates medroxyprogesterone acetate as the likely driver of the breast cancer risk. The French E3N cohort study, following over 80,000 women, confirmed that estrogen combined with bioidentical micronized progesterone did not increase breast cancer risk, while estrogen combined with synthetic progestins did.

The WHI’s breast cancer finding is a medroxyprogesterone acetate finding, not a progesterone finding. Treating all progestogenic compounds as equivalent ignores the receptor pharmacology that explains the divergence.

5. The Absolute Risk Was Small, but the Communication Was Alarming

The WHI reported its results as relative risk increases, which produced alarming-sounding numbers. The absolute risk increase in breast cancer was 8 additional cases per 10,000 women per year, or 0.08 percent. The absolute risk increase in coronary events was 7 additional cases per 10,000 women per year.

These are not trivial numbers at a population level. But they are small numbers at an individual level, and they must be weighed against the benefits of therapy (reduced fractures, reduced colorectal cancer, improved quality of life) and against the specific hormones, route, and timing that the individual patient would use.

The media coverage of the WHI communicated danger without nuance. The medical community responded with withdrawal rather than refinement. Women who would have benefited from appropriately prescribed, bioidentical, transdermal hormone therapy were denied it on the basis of a study that used different hormones, in an older population, through a riskier route.

What We Know Now

The evidence accumulated since 2002 supports a more refined position.

Hormone therapy initiated within 10 years of menopause, using transdermal bioidentical estradiol and micronized progesterone, at physiological doses, with appropriate monitoring, has a favourable risk-benefit profile for symptomatic women.

The cardiovascular data is reassuring when therapy is started early and delivered transdermally. The breast cancer data is reassuring when bioidentical progesterone is used instead of synthetic progestins. The bone, cognitive, and quality-of-life benefits are well documented.

The Endocrine Society, the North American Menopause Society, the International Menopause Society, and the British Menopause Society have all published updated position statements reflecting this more nuanced understanding.

What This Means for Patients

If you have been told that hormone therapy is dangerous based on the WHI, you have received an incomplete interpretation of the evidence.

The relevant questions are: What type of hormone? What route of delivery? At what age and time since menopause? What are your individual risk factors? What are the expected benefits for your specific symptom profile? How will hormone optimization affect your metabolic phenotype—your body composition, mitochondrial capacity, insulin sensitivity, and disease risk across systems?

A physician who can answer these questions with specificity, citing the distinction between synthetic and bioidentical hormones, between oral and transdermal delivery, and between the 2002 data and the subsequent two decades of research, is practicing evidence-informed medicine. That physician should also be measuring the systemic consequences of hormonal deficiency: the shift toward visceral adiposity, the decline in metabolic capacity, the reduction in tissue quality and resilience that untreated hormonal decline produces.

The WHI asked an important question. The answer it provided was specific to the hormones, population, and route it tested. Generalizing that answer to all hormone therapy, for all women, at all ages, was the error. Treating all untreated hormonal deficiency as safer than measured hormone replacement is another error. Correcting both is long overdue.

Continue Reading

If you found this useful, these related articles may deepen your understanding:

• Hormone Therapy and Breast Cancer Risk
• BHRT vs. Conventional HRT
• Why ‘Age-Appropriate’ Hormone Levels Are Flawed

---

Dr. Handsun Xiao is a McGill trained physician (MD, CCFP) practicing functional medicine and bioidentical hormone therapy in Toronto, with virtual consultations available to patients across Ontario. He holds advanced BHRT certification through WorldLink Medical and IFM AFMCP training. Manus Solis offers physician led BHRT consultations with custom compounding through a dedicated Ontario pharmacy partner. To learn more or book a virtual consultation, visit manussolis.ca.